← All stories
Markets
AIM movers: Hutchmed licence deal with GSK and Futura Medical assessing potential sale
Hutchmed (China) (LON: HCM) has secured a $1.3bn licensing deal for the third programme from its ATTC with GSK. HMPL-A830 is a novel KRAS small molecule inhibitor conjugated to an EGFR antibody. This combination allows the toxic payload to…
Covered by 1 outlet
All coverage · 1 article